Movement Alert｜PHARMARON Rises 6.7% in Regular Trading, CXO Sector Rallies on Earnings Delivery Momentum

Market Focus08-04

On August 4, PHARMARON rose 6.7% in regular trading, trading at 24.66 HKD/share, with turnover of 76.47 million HKD. The gain came amid a broad-based rally across the CXO sector, with peers WUXI APPTEC surging 13.08%, GENSCRIPT BIO up 7.91%, and WUXI XDC up 7.09%.

The rally is underpinned by the CXO industry entering a mid-year earnings delivery period. PHARMARON previously disclosed H1 results guidance projecting revenue of 7.47-7.67 billion yuan, representing 16%-19% year-over-year growth, while new order signings grew over 30% year-over-year, with small molecule CDMO orders surging over 50%. Global innovative drug primary market financing reached 26.75 billion USD in H1, up 58.5% year-over-year, providing sustained demand tailwinds for the contract research and manufacturing sector.

Daiwa recently initiated coverage on PHARMARON H-shares with a Buy rating and a target price of 25.5 HKD, citing robust laboratory services growth and CMC commercialization as key drivers through 2028.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124101352?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 09:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124101352","market":"us","top_or_hot":-1,"title":"Movement Alert｜PHARMARON Rises 6.7% in Regular Trading, CXO Sector Rallies on Earnings Delivery Momentum","media":"Market Focus","content":"<p><p>On August 4, PHARMARON rose 6.7% in regular trading, trading at 24.66 HKD/share, with turnover of 76.47 million HKD. The gain came amid a broad-based rally across the CXO sector, with peers WUXI APPTEC surging 13.08%, GENSCRIPT BIO up 7.91%, and WUXI XDC up 7.09%.</p><p>The rally is underpinned by the CXO industry entering a mid-year earnings delivery period. PHARMARON previously disclosed H1 results guidance projecting revenue of 7.47-7.67 billion yuan, representing 16%-19% year-over-year growth, while new order signings grew over 30% year-over-year, with small molecule CDMO orders surging over 50%. Global innovative drug primary market financing reached 26.75 billion USD in H1, up 58.5% year-over-year, providing sustained demand tailwinds for the contract research and manufacturing sector.</p><p>Daiwa recently initiated coverage on PHARMARON H-shares with a Buy rating and a target price of 25.5 HKD, citing robust laboratory services growth and CMC commercialization as key drivers through 2028.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PHARMARON Rises 6.7% in Regular Trading, CXO Sector Rallies on Earnings Delivery Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PHARMARON Rises 6.7% in Regular Trading, CXO Sector Rallies on Earnings Delivery Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-04 09:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 4, PHARMARON rose 6.7% in regular trading, trading at 24.66 HKD/share, with turnover of 76.47 million HKD. The gain came amid a broad-based rally across the CXO sector, with peers WUXI APPTEC surging 13.08%, GENSCRIPT BIO up 7.91%, and WUXI XDC up 7.09%.</p><p>The rally is underpinned by the CXO industry entering a mid-year earnings delivery period. PHARMARON previously disclosed H1 results guidance projecting revenue of 7.47-7.67 billion yuan, representing 16%-19% year-over-year growth, while new order signings grew over 30% year-over-year, with small molecule CDMO orders surging over 50%. Global innovative drug primary market financing reached 26.75 billion USD in H1, up 58.5% year-over-year, providing sustained demand tailwinds for the contract research and manufacturing sector.</p><p>Daiwa recently initiated coverage on PHARMARON H-shares with a Buy rating and a target price of 25.5 HKD, citing robust laboratory services growth and CMC commercialization as key drivers through 2028.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1124101352","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124101352","pubTimestamp":1785807459,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 4, PHARMARON rose 6.7% in regular trading, trading at 24.66 HKD/share, with turnover of 76.47 million HKD. The gain came amid a broad-based rally across the CXO sector, with peers WUXI...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势提醒|康龙化成常规交易上涨 6.7%，CXO 板块因盈利交付势头而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On August 4, PHARMARON rose 6.7% in regular trading, trading at 24.66 HKD/share, with turnover of 76.47 million HKD. The gain came amid a broad-based rally across the CXO sector, with peers WUXI APPTEC surging 13.08%, GENSCRIPT BIO up 7.91%, and WUXI XDC up 7.09%.The rally is underpinned by the CXO industry entering a mid-year earnings delivery period. PHARMARON previously disclosed H1 results guidance projecting revenue of 7.47-7.67 billion yuan, representing 16%-19% year-over-year growth, while new order signings grew over 30% year-over-year, with small molecule CDMO orders surging over 50%. Global innovative drug primary market financing reached 26.75 billion USD in H1, up 58.5% year-over-year, providing sustained demand tailwinds for the contract research and manufacturing sector.Daiwa recently initiated coverage on PHARMARON H-shares with a Buy rating and a target price of 25.5 HKD, citing robust laboratory services growth and CMC commercialization as key drivers through 2028.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124101352","isCrawlerRequest":true}